These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8121441)

  • 41. Intracoronary coagulative nightmare during recanalization of a recent total occlusion of the left anterior descending artery.
    Paolillo V; Gastaldo D
    J Invasive Cardiol; 2004 Feb; 16(2):72-5. PubMed ID: 14760195
    [No Abstract]   [Full Text] [Related]  

  • 42. Rheolytic thrombectomy: a new treatment for stent thrombosis.
    Scott LR; Silva JA; White C; Collins TJ
    Catheter Cardiovasc Interv; 1999 May; 47(1):97-101. PubMed ID: 10385170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?
    Jeremias A; Gruberg L
    J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of angioplasty with stenting in acute myocardial infarction.
    Herrmann HC
    N Engl J Med; 2002 Aug; 347(5):367-8; author reply 367-8. PubMed ID: 12151478
    [No Abstract]   [Full Text] [Related]  

  • 45. Different benefits, different risks, equal cost.
    Colombo A
    Eur Heart J; 1999 Nov; 20(21):1531-2. PubMed ID: 10529320
    [No Abstract]   [Full Text] [Related]  

  • 46. The CAPTURE trial.
    Umans VA; Kloeg PH; Bronzwaer J
    Lancet; 1997 Aug; 350(9075):445. PubMed ID: 9259679
    [No Abstract]   [Full Text] [Related]  

  • 47. [Quick resolution with abciximab of giant coronary thrombus].
    Delcán Domínguez JL; García Fernández E; Guerrero Sanz JE
    Rev Esp Cardiol; 2002 May; 55(5):536. PubMed ID: 12015935
    [No Abstract]   [Full Text] [Related]  

  • 48. Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors.
    Goldschmidt-Clermont PJ; Kandzari DE; Sketch MH; Phillips HR
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():18E-25E; quiz 26E. PubMed ID: 12668859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
    Cantor WJ; Leblanc K; Garvey B; Watson KR; Rasymas A; Strauss BH
    Catheter Cardiovasc Interv; 1999 Mar; 46(3):352-5. PubMed ID: 10348139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of platelet therapy.
    Fry JA; Grines CL
    Semin Interv Cardiol; 2000 Sep; 5(3):117-28. PubMed ID: 11054909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab in percutaneous coronary intervention in a teaching hospital setting?
    Khan JM; Watson RD; Varma C; Millane T; Lip GY
    Int J Clin Pract; 2006 Apr; 60(4):498-9. PubMed ID: 16620368
    [No Abstract]   [Full Text] [Related]  

  • 52. Instant dissolution of intracoronary thrombus by abciximab.
    Lee CH; Ho KT; Tan HC
    Int J Cardiol; 2005 Sep; 104(1):102-3. PubMed ID: 16137518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abciximab, a novel platelet-blocking drug: pharmacology and nursing implications.
    Mayer DM; Docktor WJ
    Crit Care Nurse; 1998 Apr; 18(2):29-37. PubMed ID: 9708118
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
    Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
    Moliterno DJ; Ziada KM
    J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681
    [No Abstract]   [Full Text] [Related]  

  • 56. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 57. Management of coronary artery perforation in patients receiving abciximab.
    Del Campo C; Zelman R
    Catheter Cardiovasc Interv; 2001 Sep; 54(1):139-40. PubMed ID: 11553964
    [No Abstract]   [Full Text] [Related]  

  • 58. Platelet antiaggregants in pregnancy.
    Santiago-Díaz P; Arrebola-Moreno AL; Ramírez-Hernández JA; Melgares-Moreno R
    Rev Esp Cardiol; 2009 Oct; 62(10):1197-8. PubMed ID: 19793530
    [No Abstract]   [Full Text] [Related]  

  • 59. Integrin beta3 blockade with abciximab and protection from myocardial ischemic events.
    Conrad ME; Umbreit JN; Moore EG
    JAMA; 1998 Jan; 279(3):195-6. PubMed ID: 9438735
    [No Abstract]   [Full Text] [Related]  

  • 60. Intravenous administration of monoclonal antibody to the platelet GP IIb/IIIa receptor to treat abrupt closure during coronary angioplasty.
    Anderson HV; Revana M; Rosales O; Brannigan L; Stuart Y; Weisman H; Willerson JT
    Am J Cardiol; 1992 May; 69(16):1373-6. PubMed ID: 1585878
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.